Cargando…

CGRP in migraine

Detalles Bibliográficos
Autores principales:	Tfelt-Hansen, Peer, Ashina, Messoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2009
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3452099/ https://www.ncbi.nlm.nih.gov/pubmed/19690942 http://dx.doi.org/10.1007/s10194-009-0139-x

Ejemplares similares

When to use frovatriptan in migraine?
por: Tfelt-Hansen, Peer Carsten
Publicado: (2011)

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis
por: Christensen, Casper Emil, et al.
Publicado: (2022)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

Effect of CGRP and sumatriptan on the BOLD response in visual cortex
por: Asghar, Mohammad S., et al.
Publicado: (2012)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial
por: Tfelt-Hansen, Peer
Publicado: (2011)

Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

Pharmacogenomics and migraine: possible implications
por: Tfelt-Hansen, Peer, et al.
Publicado: (2008)

Suggested randomised, controlled trial with frovatriptan
por: Tfelt-Hansen, Peer, et al.
Publicado: (2011)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

Triptans and CGRP blockade – impact on the cranial vasculature
por: Benemei, Silvia, et al.
Publicado: (2017)

Acute pharmacotherapy of migraine, tension-type headache, and cluster headache
por: Tfelt-Hansen, Peer
Publicado: (2007)

What can be learned from the history of recurrence in migraine? A comment
por: Tfelt-Hansen, Peer
Publicado: (2009)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache
por: Tfelt-Hansen, Peer Carsten
Publicado: (2011)

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment
por: Tfelt-Hansen, Peer
Publicado: (2007)

Verisimilitude (or “truthlikeness”) as an alternative to pro and cons: migraine and cluster headache mechanisms
por: Tfelt-Hansen, Peer Carsten
Publicado: (2010)

Are the current IHS guidelines for migraine drug trials being followed?
por: Hougaard, Anders, et al.
Publicado: (2010)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

The K(ATP) channel in migraine pathophysiology: a novel therapeutic target for migraine
por: Al-Karagholi, Mohammad Al-Mahdi, et al.
Publicado: (2017)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

The Effect of K(ATP) Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers
por: Coskun, Hande, et al.
Publicado: (2021)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

Therapeutic novelties in migraine: new drugs, new hope?
por: Do, Thien Phu, et al.
Publicado: (2019)

CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects
por: Evers, Stefan
Publicado: (2022)

Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment
por: Tfelt-Hansen, Peer C.
Publicado: (2009)

Anti-CGRP in cluster headache therapy: a response
por: Wenzel, Richard, et al.
Publicado: (2020)

Permeability of dura mater: a possible link between cortical spreading depression and migraine pain? A comment
por: Tfelt-Hansen, Peer Carsten
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k23eu4nae9j4dh0gi92cbt5fbv